The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in Chinese patients (pts) with HER2-positive early breast cancer (EBC): Primary analysis of the phase III, randomised FDChina study

被引：0
作者：
Shao, Z. [1 ]
Huang, T. [2 ]
Fan, Z. [3 ]
Wang, Y. [4 ]
Yan, X. [5 ]
Yang, H. [6 ]
Wang, S. [7 ]
Pang, D. [8 ]
Li, H. [9 ]
Wang, H. [10 ]
Geng, C. [11 ]
Huang, L. [12 ]
Siddiqui, A. [13 ]
Wang, B. [14 ]
Xie, B. [15 ]
Sun, G. [16 ]
Restuccia, E. [17 ]
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Breast Canc, Shanghai, Peoples R China
[2] Tongji Med Coll, Dept Breast & Thyroid Surg, Wuhan, Peoples R China
[3] Jilin Univ, Dept Breast Surg, Changchun, Peoples R China
[4] Shandong Canc Hosp, Breast Canc Ctr, Jinan, Peoples R China
[5] Sichuan Univ, West China Hosp, Med Oncol, Chengdu, Peoples R China
[6] Zhejiang Canc Hosp, Breast Surg, Hangzhou, Peoples R China
[7] Peking Univ Peoples Hosp, Breast Ctr, Beijing, Peoples R China
[8] Harbin Med Univ, Dept Breast Surg, Harbin, Peoples R China
[9] Beijing Canc Hosp, Breast Canc Ctr, Beijing, Peoples R China
[10] Affiliated Hosp Qingdao Univ, Dept Breast Ctr, Qingdao, Peoples R China
[11] Fourth Hosp Hebei Med Univ, Breast Ctr, Shijiazhuang, Hebei, Peoples R China
[12] Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, Shanghai, Peoples R China
[13] Roche Prod Ltd, Prod Dev Clin Oncol, Welwyn Garden City, Herts, England
[14] Genentech Inc, Clin Pharmacol, San Francisco, CA 94080 USA
[15] Roche China Holding Co Ltd, Biostat, Shanghai, Peoples R China
[16] Roche China Holding Co Ltd, PD China, Shanghai, Peoples R China
[17] F Hoffmann La Roche Ltd, Prod Dev Oncol, Basel, Switzerland
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1MO
引用
收藏
页码：S1431 / S1431
页数：1
相关论文
共 50 条
  • [21] Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study (vol 88, 499, 2021)
    Wang, Bei
    Deng, Rong
    Hennig, Stefanie
    Badovinac Crnjevic, Tanja
    Kaewphluk, Monika
    Kagedal, Matts
    Quartino, Angelica L.
    Girish, Sandhya
    Li, Chunze
    Kirschbrown, Whitney P.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (04) : 571 - 572
  • [22] Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study (vol 22, pg 85, 2021)
    Tan, A. R.
    Im, S-A
    Mattar, A.
    LANCET ONCOLOGY, 2021, 22 (02) : E42 - E42
  • [23] Population pharmacokinetic (PK) analysis of trastuzumab confirms the appropriateness of a fixed (non-weight-based) subcutaneous (SC) formulation dose in patients with HER2-positive early breast cancer (EBC)
    Quartino, A.
    Li, J.
    Li, H.
    Wada, D. R.
    Visich, J.
    Li, C.
    Jin, J. Y.
    Lum, B.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S44 - S44
  • [24] Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer
    Luo, Yang
    Li, Wei
    Jiang, Zefei
    Zhang, Qingyuan
    Wang, Liwei
    Mao, Yixiang
    Tjan-Heijnen, Vivianne C. G.
    Im, Seock-Ah
    McConnell, Robin
    Bejarano, Sara
    Fumagalli, Debora
    Bines, Jose
    Wang, Bei
    Garg, Amit
    Kirschbrown, Whitney P.
    Xu, Binghe
    ANTI-CANCER DRUGS, 2019, 30 (08) : 866 - 872
  • [25] heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer
    Kuemmel, Sherko
    Harper-Wynne, Catherine
    Park, Yeon Hee
    Franke, Fabio
    de Laurentiis, Michelino
    Schumacher-Wulf, Eva
    Eiger, Daniel
    Heeson, Sarah
    Cardona, Andres
    Ozyilkan, Ozgur
    Morales-Vasquez, Flavia
    Metcalfe, Ciara
    Hafner, Marc
    Restuccia, Eleonora
    O'Shaughnessy, Joyce
    BMC CANCER, 2024, 24 (01)
  • [26] Pertuzumab and trastuzumab as adjuvant treatment for HER2-positive early breast cancer: outcomes in Chinese patients in the APHINITY study
    Shao, Zhimin
    Tseng, Ling-Ming
    Huang, Chiun-Sheng
    Pang, Da
    Yang, Youngsen
    Li, Wei
    Liao, Ning
    Geng, Cuizhi
    Zhang, Qingyuan
    Xu, Binghe
    Liu, Donggeng
    Kwong, Ava
    Yu, Mandy
    Sun, Guofang
    Mobus, Volker
    Dent, Susan
    Arahmani, Amal
    Borthwick, Gillian
    Henot, Frederic
    von Minckwitz, Gunter
    Jiang, Zefei
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (03) : 345 - 353
  • [27] heredERA Breast Cancer: Phase III study of first-line, fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection ± giredestrant (GDC-9545) for estrogen receptor+, HER2+advanced breast cancer
    Kuemmel, Sherko
    Harper-Wynne, Catherine
    Park, Yeon H.
    Franke, Fabio
    De laurentiis, Michelino
    Schumacher-Wulf, Eva
    Eiger, Daniel
    Heeson, Sarah
    Shivhare, Mahesh
    Restuccia, Eleonora
    O'Shaughnessy, Joyce
    CANCER RESEARCH, 2023, 83 (05)
  • [28] Real-life data on the cardiac toxicity of adjuvant fixed-dose subcutaneous trastuzumab in HER2-positive breast cancer
    De Sanctis, R.
    D'Antonio, F.
    Agostinetto, E.
    Marinello, A.
    Masci, G.
    Zuradelli, M.
    Losurdo, A.
    Guiducci, D.
    Tinterri, C.
    Testori, A.
    Gatzemeier, W.
    Errico, V.
    Torrisi, R.
    Santoro, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 71 - 71
  • [29] COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB EMTANSINE VERSUS PERTUZUMAB WITH TRASTUZUMAB FOR CHINESE PATIENTS WITH RESIDUAL INVASIVE HER2-POSITIVE EARLY BREAST CANCER
    Guan, X.
    Li, H. C.
    Xia, Y.
    Yang, Q.
    Ma, A. X.
    VALUE IN HEALTH, 2022, 25 (07) : S372 - S372
  • [30] Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study
    Lin, Nancy U.
    Pegram, Mark
    Sahebjam, Solmaz
    Ibrahim, Nuhad
    Fung, Anita
    Cheng, Anna
    Nicholas, Alan
    Kirschbrown, Whitney
    Kumthekar, Priya
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (24) : 2667 - +
12345